You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ)攜關聯方各以不超500萬美元認購雙虹科技255.2萬股B優先股
格隆匯 08-06 18:40

格隆匯8月6日丨貝達藥業(300558.SZ)公佈,公司將以不超過500萬美元的自有資金按每股1.95921美元的價格認購DoubleRainbow Biosciences, Inc.(美國雙虹生物科技公司,簡稱“雙虹科技”)新發行的B優先股255.2047萬股。此次投資完成後,公司將持有雙虹科技4.35%股權。

同時,公司關聯人杭州貝銘股權投資基金合夥企業(有限合夥)以相同金額和價格認購雙虹科技新發行B優先股255.2047萬股。

雙虹科技是一家生命科學領域創新型公司,擁有“酶催化藥物發現平台”和“天然產物生物全合成平台”兩大創新性技術平台,基於該等技術平台,雙虹科技開發了多樣化的產品管線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account